Day: August 11, 2021

FORT WORTH, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) — Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) announced today its financial results for the second quarter ended June 30, 2021.   Second Quarter 2021 Highlights and Recent DevelopmentsProduction sales of 2,196 MBoe for the second quarter of 2021, or 24.1 MBoe per day, an increase from 1,469 MBoe, or 16.1 MBoe per day in the prior year quarter, primarily due to new production from the Mid-Con Acquisition and the Silvertip Acquisition (each as defined in our recently filed Form 10-Q for the second quarter of 2021), which closed on January 21, 2021 and February 1, 2021, respectively. Production sales volumes were also slightly higher than the upper end of production guidance provided by the Company for the quarter.Total operating expenses...

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended June 30, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.  The second quarter 2021 was marked by meaningful clinical progress. Recent HighlightsIssue Notification for patent US 11,098,005 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”. A novel process for the production of our lead investigational product SBP-101, reduces the number of synthetic steps for its production from seventeen to six, and provides patent coverage to 2039. $10.0 million bought offering of common stock closed July...

Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditionsCINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) — Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. Key Business Update:On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company (“Aadi”), and Aspen Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Aerpio (“Merger Sub”), wherby Merger Sub will merge with and into Aadi with...

MARKHAM, Ontario, Aug. 11, 2021 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today provided an update on its operations and announced its financial results for the three and six months ended June 30, 2021. The Consolidated Financial Statements and accompanying Management’s Discussion and Analysis (“MD&A”) are available on the Company’s website at www.siennaliving.ca and on SEDAR at www.sedar.com. Launch of New Retirement Platform “Aspira” “Over the past year, we conducted an in-depth assessment of our retirement operations and identified opportunities that will set us apart in a competitive market,” said Nitin Jain, President and Chief Executive Officer of Sienna. “Under the Aspira brand, our goal is to provide residents with a wider range of choices. At the centre of our new brand is...

TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales ANN ARBOR, Mich., Aug. 11, 2021 (GLOBE NEWSWIRE) — Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and six months ended June 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). Robert Cohen, Chief Executive Officer of Zomedica stated that, “I fully understand and appreciate that what all of our stakeholders, both internal and external, want to see is continued execution on our goals and the building of increased value in our business. For quite some...

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “The public health community continues to affirm the need for vaccines that can offer broader protection to prevent pneumococcal disease and, importantly, reach an expanded population including adults aged 50 and older as well as those at higher risk due to existing health conditions,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We are focused on making a significant contribution to fulfill this need with VAX-24,...

-Management to Host Conference Call on August 12 at 8am ET-Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021 SUL-DUR Launch Planning Progresses with Appointment of Anna Diaz Triola as Chief Commercial Officer Data On SUL-DUR and ETX0462 Presented at World Microbe Forum $20 Million Private Placement Transaction Completed with InnovivaWALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today financial results for the second quarter 2021 and issued a business update for the quarter and recent weeks. “During our second quarter and in recent weeks we continued to build upon the...

– Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib –– Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow –– Cash Runway to Early 2023 –– Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2021. The quarter’s business highlights included an update on the Company’s progress with fadraciclib and CYC140, Cyclacel’s novel CDK2/9 and PLK1 inhibitors, respectively. “After announcing In July that the first patient...

Resonant-Designed RF Filter Shipment Volumes Grew a Record 450% Year-Over-Year; IP Portfolio Expands to over 375 Filed or Issued Patents AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today provided financial results for the second quarter ended June 30, 2021. Management Commentary “The second quarter of 2021 was marked by accelerating customer shipments of a record 17.5 million RF filters, continued advancements in our XBAR® RF filter technology to unlock next-generation networks and financial results in-line with previously issued guidance,” said George B. Holmes, Chairman and CEO of Resonant. “We continue to receive validation from industry leaders that...

Completed investigational new drug (“IND”) enabling studies for lead program, BMF-219, an irreversibly binding menin inhibitor. On track to complete IND submission for Phase I/II study of BMF-219 as treatment for patients with menin-dependent acute myeloid leukemia (“AML”) and acute lymphocytic leukemia (“ALL”) during the second half of this year Continued to advance ongoing preclinical studies of BMF-219 in a number of menin-dependent liquid and solid tumors, including Diffuse Large B Cell Lymphoma (“DLBCL”), to expand potential impact of novel drug    Initiated pathway validation studies in type 2 diabetes Continued to expand team and laboratory facilities to support long-term growth and clinical and preclinical development plans Strengthened Board of Directors with appointment of Sumita Ray, J.D., Chief Legal and Administrative Officer...